Showing results (51-60 of 119) with videos related to

Sort By:
Pageof 12
Journal of Gastrointestinal Oncology|July 25, 2017
Comparison of efficacy and toxicity of FOLFIRINOX and gemcitabine with nab-paclitaxel in unresectable pancreatic cancerTetsuhito Muranaka, Masaki Kuwatani, Yoshito Komatsu, et al.
Investigational New Drugs|October 4, 2011
Phase I dose-escalating study of panobinostat (LBH589) administered intravenously to Japanese patients with advanced solid tumorsSachi Morita, Satoshi Oizumi, Hironobu Minami, et al.
Therapeutic Advances in Medical Oncology|November 16, 2020
Practical considerations in the use of regorafenib in metastatic colorectal cancerFotios Loupakis, Lorenzo Antonuzzo, Jean-Baptiste Bachet, et al.
Cancer Medicine|February 19, 2022
The survival benefit of increasing the number of active drugs for metastatic colorectal cancer: A multicenter retrospective studyTakeshi Kawakami, Toshiki Masuishi, Yasuyuki Kawamoto, et al.
Investigational New Drugs|December 22, 2010
Phase II study of combination chemotherapy with biweekly cetuximab and irinotecan for wild-type KRAS metastatic colorectal cancer refractory to irinotecan, oxaliplatin, and fluoropyrimidinesKohei Shitara, Satoshi Yuki, Motoki Yoshida, et al.
Oncology|July 9, 2020
Multicenter Cohort Study to Assess the Association between Changes on Imaging and Outcome after Regorafenib Treatment (KSCC1603)Eiji Oki, Masahiro Kawahira, Tetsuya Kusumoto, et al.
The Oncologist|July 7, 2021
The Prognostic Impact of KRAS G12C Mutation in Patients with Metastatic Colorectal Cancer: A Multicenter Retrospective Observational StudyKeigo Chida, Daisuke Kotani, Toshiki Masuishi, et al.
BMC Cancer|June 8, 2021
REMARRY and PURSUIT trials: liquid biopsy-guided rechallenge with anti-epidermal growth factor receptor (EGFR) therapy with panitumumab plus irinotecan for patients with plasma RAS wild-type metastatic colorectal cancerHiromichi Nakajima, Daisuke Kotani, Hideaki Bando, et al.
ESMO Open|May 12, 2020
Impact of tumour growth rate during preceding treatment on tumour response to regorafenib or trifluridine/tipiracil in refractory metastatic colorectal cancerToshiki Masuishi, Hiroya Taniguchi, Takeshi Kawakami, et al.
Nihon Rinsho. Japanese Journal of Clinical Medicine|March 25, 2004
[Immunological rapid urease test]Mototsugu Kato, Soichi Nakagawa, Yuichi Shimizu, et al.
Pageof 12